Markers of bone turnover in Gaucher disease: Modeling the evolution of bone disease

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 7, 2011, Pages 2194-2205

  Van Dussen, L ^a   Lips, P ^b   Everts, V E ^a   Bravenboer, N ^b   Jansen, I D C ^a   Groener, J E M ^a   Maas, M ^a   Blokland, J A K ^c   Aerts, J M F G ^a   Hollak, Carla E M ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; CARBOXY TERMINAL TELOPEPTIDE; CHITOTRIOSIDASE; OSTEOCALCIN;

ADOLESCENT; ADULT; AGED; ARTICLE; AVASCULAR NECROSIS; BONE DISEASE; BONE MARROW; BONE TURNOVER; CLINICAL ARTICLE; COHORT ANALYSIS; DISEASE SEVERITY; ENZYME ACTIVITY; FEMALE; FRACTURE; GAUCHER DISEASE; HUMAN; MALE; OSSIFICATION; OSTEOLYSIS; OSTEOMYELITIS; OSTEOPENIA; OSTEOPOROSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; BONE RESORPTION; COLLAGEN TYPE I; DISEASE PROGRESSION; FEMALE; GAUCHER DISEASE; HUMANS; MALE; MIDDLE AGED; OSTEOCALCIN; OSTEOGENESIS; PEPTIDES; PROCOLLAGEN; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 79960105516     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-0162     Document Type: Article

References (50)

1. Beutler E, Grabowski GA 2001 Gaucher disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic and molecular bases of inherited disease. 8th ed. New York: McGraw-Hill; 3636
2. Poorthuis BJ, Wevers RA, Kleijer WJ, Groener JE, de Jong JG, van Weely S, Niezen-Koning KE, van Diggelen OP 1999 The frequency of lysosomal storage diseases in The Netherlands. Hum Genet 105: 151-156 (Pubitemid 29396979)
3. Brady RO, Kanfer JN, Shapiro D 1965 Metabolism of glucocerebrosides. II. Evidence of an enzymatic deficiency in Gaucher's disease. Biochem Biophys Res Commun 18:221-225
4. Patrick AD 1965 Short communications: a deficiency of glucocerebrosidase in Gaucher's disease. Biochem J 97:17C-18C
5. Biegstraaten M, van Schaik IN, Aerts JM, Hollak CE 2008 'Nonneuronopathic' Gaucher disease reconsidered. Prevalence of neurological manifestations in a Dutch cohort of type I Gaucher disease patients and a systematic review of the literature. J Inherit Metab Dis 31:337-349
6. Brady RO, Pentchev PG, Gal AE, Hibbert SR, Dekaban AS 1974 Replacement therapy for inherited enzyme deficiency. Use of purified glucocerebrosidase in Gaucher's disease. N Engl J Med 291: 989-993
7. Grabowski GA, Barton NW, Pastores G, Dambrosia JM, Banerjee TK, McKee MA, Parker C, Schiffmann R, Hill SC, Brady RO 1995 Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med 122:33-39
8. Cox T, Lachmann R, Hollak C, Aerts J, van Weely S, Hrebicek M, Platt F, Butters T, Dwek R, Moyses C, Gow I, Elstein D, Zimran A 2000 Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 355:1481-1485 (Pubitemid 30237353)
9. Hollak C, Maas M, Akkerman E, den Heeten A, Aerts H 2001 Dixon quantitative chemical shift imaging is a sensitive tool for the evaluation of bone marrow responses to individualized doses of enzyme supplementation therapy in type 1 Gaucher disease. Blood Cells Mol Dis 27:1005-1012 (Pubitemid 34163969)
10. Ciana G, Addobbati R, Tamaro G, Leopaldi A, Nevyjel M, Ronfani L, Vidoni L, Pittis MG, Bembi B 2005 Gaucher disease and bone: laboratory and skeletal mineral density variations during a long period of enzyme replacement therapy. J Inherit Metab Dis 28:723-732 (Pubitemid 41349260)
11. Schiffmann R, Mankin H, Dambrosia JM, Xavier RJ, Kreps C, Hill SC, Barton NW, Rosenthal DI 2002 Decreased bone density in splenectomized Gaucher patients receiving enzyme replacement therapy. Blood Cells Mol Dis 28:288-296 (Pubitemid 34743762)
12. de Fost M, van Noesel CJ, Aerts JM, Maas M, Pöll RG, Hollak CE 2008 Persistent bone disease in adult type 1 Gaucher disease despite increasing doses of enzyme replacement therapy. Haematologica 93:1119-1120 (Pubitemid 351957043)
13. Harinck HI, Bijvoet OL, van der Meer JW, Jones B, Onvlee GJ 1984 Regression of bone lesions in Gaucher's disease during treatment with aminohydroxypropylidene bisphosphonate. Lancet 2:513 (Pubitemid 14069777)
14. Stowens DW, Teitelbaum SL, Kahn AJ, Barranger JA 1985 Skeletal complications of Gaucher disease. Medicine (Baltimore) 64:310-322 (Pubitemid 16224046)
15. Moran MT, Schofield JP, Hayman AR, Shi GP, Young E, Cox TM 2000 Pathologic gene expression in Gaucher disease: up-regulation of cysteine proteinases including osteoclastic cathepsin K. Blood 96:1969-1978 (Pubitemid 30662113)
16. Ciana G, Cuttini M, Bembi B 1997 Short-term effects of pamidronate in patients with Gaucher's disease and severe skeletal involvement. N Engl J Med 337:712 (Pubitemid 27375485)
17. Ostlere L, Warner T, Meunier PJ, Hulme P, Hesp R, Watts RW, Reeve J 1991 Treatment of type 1 Gaucher's disease affecting bone with aminohydroxypropylidene bisphosphonate (pamidronate). Q J Med 79:503-515
18. Samuel R, Katz K, Papapoulos SE, Yosipovitch Z, Zaizov R, Liberman UA 1994 Aminohydroxy propylidene bisphosphonate (APD) treatment improves the clinical skeletal manifestations of Gaucher's disease. Pediatrics 94:385-389 (Pubitemid 24271485)
19. Wenstrup RJ, Bailey L, Grabowski GA, Moskovitz J, Oestreich AE, Wu W, Sun S 2004 Gaucher disease: alendronate disodium improves bone mineral density in adults receiving enzyme therapy. Blood 104: 1253-1257 (Pubitemid 39166496)
20. Sims KB, Pastores GM, Weinreb NJ, Barranger J, Rosenbloom BE, Packman S, Kaplan P, Mankin H, Xavier R, Angell J, Fitzpatrick MA, Rosenthal D 2008 Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study. Clin Genet 73:430-440 (Pubitemid 351517258)
21. Cox TM, Aerts JM, Belmatoug N, Cappellini MD, vom Dahl S, Goldblatt J, Grabowski GA, Hollak CE, Hwu P, Maas M, Martins AM, Mistry PK, Pastores GM, Tylki-Szymanska A, Yee J, Weinreb N 2008 Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring. J Inherit Metab Dis 31:319-336
22. Ciana G, Martini C, Leopaldi A, Tamaro G, Katouzian F, Ronfani L, Bembi B 2003 Bone marker alterations in patients with type 1 Gaucher disease. Calcif Tissue Int 72:185-189 (Pubitemid 36919522)
23. Drugan C, Jebeleanu G, Grigorescu-Sido P, Caillaud C, Craciun AM 2002 Biochemical markers of bone turnover as tools in the evaluation of skeletal involvement in patients with type 1 Gaucher disease. Blood Cells Mol Dis 28:13-20 (Pubitemid 34408983)
24. Aerts JM, Donker-Koopman WE, van der Vliet MK, Jonsson LM, Ginns EI, Murray GJ, Barranger JA, Tager JM, Schram AW 1985 The occurrence of two immunologically distinguishable β-glucocerebrosidases in human spleen. Eur J Biochem 150:565-574 (Pubitemid 15024833)
25. Christenson RH 1997 Biochemical markers of bone metabolism: an overview. Clin Biochem 30:573-593 (Pubitemid 28116790)
26. Brown JP, Delmas PD, Malaval L, Edouard C, Chapuy MC, Meunier PJ 1984 Serum bone Gla-protein: a specific marker for bone formation in postmenopausal osteoporosis. Lancet 1:1091-1093 (Pubitemid 14100805)
27. Zimran A, Kay A, Gelbart T, Garver P, Thurston D, Saven A, Beutler E 1992 Gaucher disease. Clinical, laboratory, radiologic, and genetic features of 53 patients. Medicine (Baltimore) 71:337-353
28. Maas M, Hollak CE, Akkerman EM, Aerts JM, Stoker J, DenHeeten GJ 2002 Quantification of skeletal involvement in adults with type I Gaucher's disease: fat fraction measured by Dixon quantitative chemical shift imaging as a valid parameter. AJR Am J Roentgenol 179:961-965
29. Maas M, van Kuijk C, Stoker J, Hollak CE, Akkerman EM, Aerts JF, den Heeten GJ 2003 Quantification of bone involvement in Gaucher disease:MRimaging bone marrow burden score as an alternative to Dixon quantitative chemical shift MR imaging-initial experience. Radiology 229:554-561 (Pubitemid 37310846)
30. Aguilera B, Ghauharali-van der Vlugt K, Helmond MT, Out JM, Donker-Koopman WE, Groener JE, Boot RG, Renkema GH, van der Marel GA, van Boom JH, Overkleeft HS, Aerts JM 2003 Transglycosidase activity of chitotriosidase: improved enzymatic assay for the human macrophage chitinase. J Biol Chem 278:40911-40916 (Pubitemid 37280911)
31. Schoonhoven A, Rudensky B, Elstein D, Zimran A, Hollak CE, Groener JE, Aerts JM 2007 Monitoring of Gaucher patients with a novel chitotriosidase assay. Clin Chim Acta 381:136-139 (Pubitemid 46719145)
32. Boot RG, Renkema GH, Verhoek M, Strijland A, Bliek J, de Meulemeester TM, Mannens MM, Aerts JM 1998 The human chitotriosidase gene. Nature of inherited enzyme deficiency. J Biol Chem 273:25680-25685
33. Eastell R, Chen P, Saag KG, Burshell AL, Wong M, Warner MR, Krege JH 2010 Bone formation markers in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate. Bone 46:929-934
34. Allen MJ, Myer BJ, Khokher AM, Rushton N, Cox TM 1997 Proinflammatory cytokines and the pathogenesis of Gaucher's disease: increased release of interleukin-6 and interleukin-10. Q J Med 90: 19-25 (Pubitemid 27075848)
35. Barak V, Acker M, Nisman B, Kalickman I, Abrahamov A, Zimran A, Yatziv S 1999 Cytokines in Gaucher's disease. Eur Cytokine Netw 10:205-210 (Pubitemid 29332776)
36. Hollak CE, Evers L, Aerts JM, van Oers MH 1997 Elevated levels of M-CSF, sCD14 and IL8 in type 1 Gaucher disease. Blood Cells Mol Dis 23:201-212 (Pubitemid 27469455)
37. Michelakakis H, Spanou C, Kondyli A, Dimitriou E, Van Weely S, Hollak CE, Van Oers MH, Aerts JM 1996 Plasma tumor necrosis factor-a (TNF-a) levels in Gaucher disease. Biochim Biophys Acta 1317:219-222 (Pubitemid 26426550)
38. Moller HJ, de Fost M, Aerts H, Hollak C, Moestrup SK 2004 Plasma level of the macrophage-derived soluble CD163 is increased and positively correlates with severity in Gaucher's disease. Eur J Haematol 72:135-139 (Pubitemid 38161162)
39. van Breemen MJ, de Fost M, Voerman JS, Laman JD, Boot RG, Maas M, Hollak CE, Aerts JM, Rezaee F 2007 Increased plasma macrophage inflammatory protein (MIP)-1α and MIP-1β levels in type 1 Gaucher disease. Biochim Biophys Acta 1772:788-796 (Pubitemid 46891215)
40. Boven LA, van Meurs M, Boot RG, Mehta A, Boon L, Aerts JM, Laman JD 2004 Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages. Am J Clin Pathol 122:359-369 (Pubitemid 39145540)
41. Mistry PK, Liu J, Yang M, Nottoli T, McGrath J, Jain D, Zhang K, Keutzer J, Chuang WL, Mehal WZ, Zhao H, Lin A, Mane S, Liu X, Peng YZ, Li JH, Agrawal M, Zhu LL, Blair HC, Robinson LJ, Iqbal J, Sun L, Zaidi M 2010 Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage. Proc Natl Acad Sci USA 107: 19473-19478
42. Sherman SS, Tobin JD, Hollis BW, Gundberg CM, Roy TA, Plato CC 1992 Biochemical parameters associated with low bone density in healthy men and women. J Bone Miner Res 7:1123-1130
43. Fatayerji D, Eastell R 1999 Age-related changes in bone turnover in men. J Bone Miner Res 14:1203-1210 (Pubitemid 29314065)
44. Glover SJ, Garnero P, Naylor K, Rogers A, Eastell R 2008 Establishing a reference range for bone turnover markers in young, healthy women. Bone 42:623-630
45. Charles P, Poser JW, Mosekilde L, Jensen FT 1985 Estimation of bone turnover evaluated by 47Ca-kinetics. Efficiency of serum bone gamma-carboxyglutamic acid-containing protein, serum alkaline phosphatase, and urinary hydroxyproline excretion. J Clin Invest 76:2254-2258 (Pubitemid 16155520)
46. Gundberg CM, Weinstein RS 1986 Multiple immunoreactive forms of osteocalcin in uremic serum. J Clin Invest 77:1762-1767 (Pubitemid 16062627)
47. Ivaska KK, Hentunen TA, Vääräniemi J, Ylipahkala H, Pettersson K, Väänänen HK 2004 Release of intact and fragmented osteocalcin molecules from bone matrix during bone resorption in vitro. J Biol Chem 279:18361-18369 (Pubitemid 38623251)
48. Gimble JM, Robinson CE, Wu X, Kelly KA 1996 The function of adipocytes in the bone marrow stroma: an update. Bone 19:421-428
49. Hangartner TN, Johnston CC 1990 Influence of fat on bone measurements with dual-energy absorptiometry. Bone Miner 9:71-81 (Pubitemid 20100902)
50. Kuiper JW, van Kuijk C, Grashuis JL, Ederveen AG, Schütte HE 1996 Accuracy and the influence of marrow fat on quantitative CT and dual-energy X-ray absorptiometry measurements of the femoral neck in vitro. Osteoporos Int 6:25-30 (Pubitemid 26046665)